Provided by Tiger Trade Technology Pte. Ltd.

Indaptus Therapeutics, Inc.

1.78
0.0000
Post-market: 1.780.00000.00%19:04 EDT
Volume:7.75K
Turnover:13.62K
Market Cap:3.99M
PE:-0.08
High:1.78
Open:1.73
Low:1.73
Close:1.78
52wk High:19.91
52wk Low:1.52
Shares:2.24M
Float Shares:985.10K
Volume Ratio:0.35
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-21.5800
EPS(LYR):-21.5800
ROE:-587.59%
ROA:-148.91%
PB:1.27
PE(LYR):-0.08

Loading ...

Company Profile

Company Name:
Indaptus Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
5
Office Location:
Three Columbus Circle,15th Floor,New York,New York,United States
Zip Code:
10019
Fax:
- -
Introduction:
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Directors

Name
Position
David E. Lazar
Chairman and Co-Chief Executive Officer
Jeffrey A. Meckler
Co-Chief Executive Officer and Director
Anthony J. Maddaluna
Director
Avraham Ben Tzvi
Director
David Natan
Director
Jerome Jabbour
Director
Matthew McMurdo
Director
Roger J. Pomerantz
Director
William B. Hayes
Director

Shareholders

Name
Position
David E. Lazar
Chairman and Co-Chief Executive Officer
Jeffrey A. Meckler
Co-Chief Executive Officer and Director
Walt A. Linscott
Chief Operating Officer
Nir Sassi
Chief Financial Officer
Michael J. Newman
Chief Scientific Officer